Abstract
Mitomycin C (MMC) is a DNA-alkylating chemotherapeutic agent most commonly used in the treatment of adenocarcinomas of the gastrointestinal tract. Cutaneous extravasation reactions are rare, yet when present, cause severe tissue injury with necrosis and ulceration at the site of infusion or a distant peripheral vascular site, either acutely or in a delayed manner. During a two-month period at a single academic hospital system, necrotic ulcers on the distal upper extremities were seen in four patients with anal cancer following MMC administration.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
